Annual Report and Accounts Delayed
Source: RNS
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Publication of Annual Report and Accounts Delayed
Suspension of Shares
29 December 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that due to delays in completing the audit for the year ended 30 June 2022, it will not publish its annual report and accounts by 31 December 2022. Consequently, the shares of the Company will be suspended from trading from 7.30am on 3 January 2023.
The Company announced its unaudited preliminary results on 29 September 2022, and it is not aware of any material change that will be required to be made to the results, and it is actively working to finalise the audit and publication of its annual report and accounts.
As previously announced, the Company is actively reviewing all funding options following the voluntary pause in production that has led to the need for significant additional near-term funding. The Company is in active discussions on funding and will update the market in due course.
For further information on the Company, please visit the website: www.allergytherapeutics.com.
This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0)1903 845 820
Manuel Llobet, Chief Executive Officer
Martin Hopcroft, Interim Chief Financial Officer
Panmure Gordon (Nominated Adviser and Broker)
+44 (0)20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 (0)20 3709 5700
Mary-Jane Elliott / David Daley / Davide Salvi
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which employs c.600 employees, is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
